Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
EIKCS 2022: Treatment for non-clear cell kidney cancer subtypes
At the European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]
Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival
A recent study published in JAMA Network Open looked at [...]
ASCO 2020: Subtypes of kidney cancer differ in sites of metastases
A paper presented during the 2020 American Society of Clinical [...]
Diagnostic biomarkers for rare subtype of kidney cancer
There are more than 10 different subtypes of renal cell [...]
Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma
In this video interview from Practice Update, Dr Brad McGregor [...]
Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma
Nivolumab alone and in combination with ipilimumab is used for [...]
ASCO 2019: First-line pembrolizumab for advanced kidney cancer
Two presentations on the results of the KEYNOTE-427 clinical trial [...]
Clinical course and treatment outcomes of sarcomatoid chromophobe RCC
Chromophobe renal cell carcinoma (RCC) is a rare subtype of [...]
Clinical characteristics and genomic alterations associated with outcome in chromophobe RCC
A recent study by researchers in New York, USA, and [...]
